Merus NV is planning to raise about $55.8 million in a private placement of 3.1 million common shares at $18 apiece to investors.

The Netherlands-based immuno-oncology company will sell the common shares to Biotechnology Value Fund LP and some of its affiliates, Aquilo Capital Management, Sofinnova Venture Partners LP and LSP Life Sciences Fund NV.

Merus plans to use the proceeds to fund product candidates and for general corporate purposes.

The offering is expected to close on or about Feb. 15.